{"filing":{"accession_number":"0001193125-26-245484","cik":"0001737287","ticker":"ALLO","company_name":"Allogene Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"d65280d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/d65280d8k.htm"},"events":[{"id":8456,"run_id":7422,"accession_number":"0001193125-26-245484","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The filing discloses the appointment of Zachary Roberts, M.D., Ph.D. as President and Chief Executive Officer effective July 1, 2026, replacing David Chang. While the section also covers Dr. Chang's departure and compensatory arrangements for Dr. Roberts, the principal disclosed action centers on the appointment of a new CEO—a material executive change. The filing provides detailed background on Dr. Roberts' qualifications and his appointment to the Board, making the appointment the salient event.","company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","filing_date":"2026-05-28","form":"8-K","submitted_at":null,"items":[{"id":2349,"accession_number":"0001193125-26-245484","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Zachary Roberts, M.D., Ph.D. as President and Chief Executive Officer effective July 1, 2026, replacing David Chang. While the section also covers Dr. Chang's departure and compensatory arrangements for Dr. Roberts, the principal disclosed action centers on the appointment of a new CEO—a material executive change. The filing provides detailed background on Dr. Roberts' qualifications and his appointment to the Board, making the appointment the salient event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:39:51.456784+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2349,"accession_number":"0001193125-26-245484","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Zachary Roberts, M.D., Ph.D. as President and Chief Executive Officer effective July 1, 2026, replacing David Chang. While the section also covers Dr. Chang's departure and compensatory arrangements for Dr. Roberts, the principal disclosed action centers on the appointment of a new CEO—a material executive change. The filing provides detailed background on Dr. Roberts' qualifications and his appointment to the Board, making the appointment the salient event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:39:51.456784+00:00","company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","filing_date":"2026-05-28"}]}